How 4DMedical’s CT:VQ™ Is Gaining Ground at Stanford Ahead of FDA Approval

• Renewed one-year subscription with Stanford’s 3DQ Lab
• Inclusion of CT – VQ™ for research prior to FDA approval
• Stanford licenses CT LVAS™ and AI-based IQ-UIP™ alongside CT – VQ™
• Contract allows up to 20,000 CT scan analyses annually
• Partnership validates 4DMedical’s advanced lung imaging tech

Renewed Partnership with a Leading Medical Innovator

4DMedical Limited, an Australian medical technology company specialising in respiratory imaging, has announced a significant renewal and expansion of its contract with Stanford University’s 3D Quantitative Imaging Laboratory (3DQ Lab). This move not only extends their collaboration but also introduces 4DMedical’s cutting-edge CT, VQ™ technology into Stanford’s research portfolio ahead of its anticipated FDA clearance.

Stanford’s 3DQ Lab is renowned globally for its role in validating and integrating next-generation imaging technologies into clinical practice. Its endorsement is often seen as a bellwether for wider adoption within the U.S. healthcare system, making this contract expansion a notable vote of confidence in 4DMedical’s technology suite.

Expanding the Suite of Advanced Imaging Tools

Under the renewed one-year subscription, Stanford has licensed a comprehensive package of 4DMedical’s products, including the fully automated CT Lung Ventilation Analysis Software (CT LVAS™) and the AI-driven IQ-UIP™ tool, which assists in diagnosing fibrotic lung diseases. The standout addition is CT, VQ™, a contrast-free ventilation and perfusion imaging solution that offers a safer and more scalable alternative to traditional nuclear medicine scans.

This expanded agreement permits up to 20,000 CT scan analyses annually, reflecting Stanford’s commitment to integrating these tools into both research and clinical workflows. The inclusion of CT, VQ™ ahead of FDA clearance underscores the technology’s potential to transform pulmonary imaging by providing detailed functional insights without the risks associated with radioactive tracers.

Strategic Implications for 4DMedical’s U.S. Market Growth

For 4DMedical, this partnership is more than a contract renewal; it is a strategic milestone that accelerates clinical validation and market readiness in the critical U.S. healthcare market. CEO Andreas Fouras highlighted Stanford’s role as a key opinion leader and the importance of their early adoption of CT, VQ™ in driving both clinical insight and commercial momentum.

With the U.S. representing a major growth opportunity, collaborations with prestigious academic medical centres like Stanford are pivotal. They not only provide rigorous clinical evaluation but also help shape healthcare standards and adoption pathways for innovative technologies.

4DMedical’s broader portfolio, including its patented XV Technology® platform and recent acquisition of AI specialist Imbio, positions the company at the forefront of respiratory diagnostics, combining advanced imaging with artificial intelligence to enhance diagnostic precision and patient care.

Looking Ahead

As 4DMedical moves closer to FDA clearance for CT, VQ™, the expanded Stanford contract signals growing confidence in the technology’s potential to redefine lung health diagnostics. The coming months will be critical for monitoring regulatory progress and the impact of clinical data emerging from this collaboration.

Bottom Line?

The expanded Stanford partnership propels 4DMedical’s CT – VQ™ closer to U.S. market breakthrough, setting the stage for transformative lung imaging adoption.

Questions in the middle?

• When exactly is FDA clearance for CT, VQ™ expected, and what are the regulatory hurdles remaining?
• How will the expanded contract translate into revenue growth and commercial uptake in the near term?
• What clinical insights or validation results will Stanford’s 3DQ Lab publish from their CT, VQ™ research?